BIOTRICITY INC. Financial Summary

Quick Answer

BIOTRICITY INC. reported Total Revenue of $13.79 million for fiscal year 2025.

BIOTRICITY INC. — Key Financials by Year

Metric 2025 2024 2023 2022 2021 2020
Total Revenue $13.79M
+14.3%
$12.06M
+25.2%
$9.64M
+26.0%
$7.65M
+126.0%
$3.38M
+138.7%
$1.42M
+256.0%
Revenue (ASC 606) $13.79M
+14.3%
$12.06M
+25.2%
$9.64M
+26.0%
$7.65M
+126.0%
$3.38M
+138.7%
$1.42M
+256.0%
Net Income -$8.42M
+40.3%
-$14.09M
+24.5%
-$18.66M
+35.9%
-$29.13M
-88.0%
-$15.49M
-40.0%
-$11.07M
-28.8%
Diluted EPS -$0.56
+66.6%
-$1.66
+26.4%
-$2.26
Total Assets $5.64M
-5.1%
$5.94M
-8.7%
$6.51M
-61.0%
$16.68M
+275.8%
$4.44M
+121.4%
$2.00M
+308.5%
Cash and Equivalents $365.1K
-53.5%
$786.1K
+37.8%
$570.5K
-95.3%
$12.07M
+448.1%
$2.20M
+131.8%
$949.8K
+1392.4%
Stockholders Equity -$32.01M
-1.7%
-$31.47M
-58.6%
-$19.85M
-825.3%
-$2.14M
+68.6%
-$6.83M
-127.7%
-$3.00M
-68.8%
R&D Expense $2.16M
-16.2%
$2.57M
-20.4%
$3.23M
+17.7%
$2.74M
+33.3%
$2.06M
+51.0%
$1.36M
+4.1%
Operating Income -$2.45M
+72.3%
-$8.83M
+42.7%
-$15.41M
+7.9%
-$16.74M
Gross Profit $10.56M
+26.4%
$8.36M
+53.6%
$5.44M
+19.1%
$4.57M
+259.1%
$1.27M
+162.0%
$485.8K
+711.4%
Shares Outstanding 26.08M
+178.8%
9.35M
+9.9%
8.51M
-82.9%
49.81M
+37.9%
36.12M
+10.8%
32.59M
+5.0%

Most Recent Quarter

Metric Quarter Ending Value YoY QoQ
Total Revenue December 31, 2025 $3.99M +10.2% +2.6%
Revenue (ASC 606) December 31, 2025 $3.99M +10.2% +2.6%
Net Income December 31, 2025 -$717.1K +41.7% -3.8%
Diluted EPS December 31, 2025 -$0.04 +22.2% -44.8%
Total Assets December 31, 2025 $5.69M -5.0% -10.1%
Cash and Equivalents December 31, 2025 $256.4K -49.7% -16.9%
Stockholders Equity December 31, 2025 -$34.24M -7.2% -2.5%
R&D Expense December 31, 2025 $623.6K +13.1% +3.4%
Operating Income December 31, 2025 $440.9K +360.9% +61.0%
Gross Profit December 31, 2025 $3.25M +17.6% +2.2%
Shares Outstanding December 31, 2025 27.81M +14.0% +3.8%
  • BIOTRICITY INC. reported Total Revenue of $13.79 million for fiscal year 2025.
  • BIOTRICITY INC. showed an increase of +14.3% in Total Revenue compared to the prior fiscal year.
  • BIOTRICITY INC. reported Revenue (ASC 606) of $13.79 million for fiscal year 2025.
  • BIOTRICITY INC. showed an increase of +14.3% in Revenue (ASC 606) compared to the prior fiscal year.
  • BIOTRICITY INC. reported Net Income of -$8.42 million for fiscal year 2025.
  • BIOTRICITY INC. showed an increase of +40.3% in Net Income compared to the prior fiscal year.
  • BIOTRICITY INC. reported Diluted EPS of $0.56 per share (loss) for fiscal year 2025.
  • BIOTRICITY INC. showed an increase of +66.6% in Diluted EPS compared to the prior fiscal year.
  • BIOTRICITY INC. reported Total Assets of $5.64 million for fiscal year 2025.
  • BIOTRICITY INC. showed a decrease of -5.1% in Total Assets compared to the prior fiscal year.
  • BIOTRICITY INC. reported Cash and Equivalents of $365.1 thousand for fiscal year 2025.
  • BIOTRICITY INC. showed a decrease of -53.5% in Cash and Equivalents compared to the prior fiscal year.
  • BIOTRICITY INC. reported Stockholders Equity of -$32.01 million for fiscal year 2025.
  • BIOTRICITY INC. showed a decrease of -1.7% in Stockholders Equity compared to the prior fiscal year.
  • BIOTRICITY INC. reported R&D Expense of $2.16 million for fiscal year 2025.
  • BIOTRICITY INC. showed a decrease of -16.2% in R&D Expense compared to the prior fiscal year.
  • BIOTRICITY INC. reported Operating Income of -$2.45 million for fiscal year 2025.
  • BIOTRICITY INC. showed an increase of +72.3% in Operating Income compared to the prior fiscal year.
  • BIOTRICITY INC. reported Gross Profit of $10.56 million for fiscal year 2025.
  • BIOTRICITY INC. showed an increase of +26.4% in Gross Profit compared to the prior fiscal year.
  • BIOTRICITY INC. reported Shares Outstanding of 26.08 million shares for fiscal year 2025.
  • BIOTRICITY INC. showed an increase of +178.8% in Shares Outstanding compared to the prior fiscal year.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment